Functional Neuroimaging Effects of the N-methyl-D-aspartate Receptor (NMDAR) Partial Agonist, GLYX-13, on Learning and Memory in Healthy Individuals
Latest Information Update: 24 Apr 2023
Price :
$35 *
At a glance
- Drugs Rapastinel (Primary)
- Indications Major depressive disorder
- Focus Pharmacodynamics
- 14 Jan 2022 Status changed from completed to discontinued.
- 26 Jan 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 05 Oct 2015 Planned End Date changed from 1 Aug 2016 to 1 Aug 2017 as reported by ClinicalTrials.gov record.